Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Lung Transplant Rejection
Interventions: macitentan, placebo (for macitentan); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke, Acute
Interventions: Oxygen, placebo; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Colorado Springs, Colorado

Conditions: Acne Vulgaris
Interventions: Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%; Drug
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Arlington Hts., Illinois

Conditions: Depression, Anhedonia
Interventions: Continuous theta burst stimulation (cTBS), Positive Affect Training, Ketamine Injectable Solution; Device · Behavioral · Drug
Lead sponsor: Erika Forbes; Other
Eligibility: 15 Years to 25 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pain, Postoperative, Opioid Use
Interventions: Intravenous Lidocaine Infusion, Placebo Infusion; Drug
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Hypothyroidism
Interventions: Levothyroxine Pill, Placebo; Drug
Lead sponsor: Spyridoula Maraka; Other
Eligibility: 65 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida • Rochester, Minnesota

Conditions: Gastroparesis
Interventions: Gastric Electrical Stimulator, Enterra, Medtronics, Inc.; Device
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Psoriatic Arthritis
Interventions: Placebo, Risankizumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 59
States / cities: Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more

Conditions: Down Syndrome
Interventions: Placebo, RG1662; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 30 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: La Jolla, California • Sacramento, California • Decatur, Georgia + 6 more

Conditions: Post Operative Pain
Interventions: Lidocaine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Cognition, BDNF
Interventions: d-beta-hydroxybutrate, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Opioid-induced Constipation
Interventions: ALKS 37, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Mesa, Arizona • Phoenix, Arizona • National City, California + 17 more

Conditions: Heart Failure, Worsening Heart Failure (WHF)
Interventions: Placebo, R2R01; Drug
Lead sponsor: River 2 Renal Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 8
States / cities: Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more

Conditions: Dry Eye
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more

Conditions: HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions: Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute-graft-versus-host Disease
Interventions: AAT, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more

Conditions: Healthy
Interventions: LY2541546 - SC, LY2541546 - IV, Placebo - SC, Placebo - IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Daytona Beach, Florida • Honolulu, Hawaii • Evansville, Indiana + 2 more

Conditions: Acute Gouty Arthritis
Interventions: Anakinra 100 mg, Triamcinolone Acetonide 40 mg, Placebo to Anakinra 100 mg, Placebo to Triamcinolone Acetonide 40 mg; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 32 more

Conditions: Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions: Estradiol Vaginal Capsule (EVC), Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more

Conditions: Hepatitis C Virus Infection
Interventions: LDV/SOF, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End Stage Renal Disease
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Sleep, Mood, Cognitive Performance
Interventions: Proprietary Spearmint Extract Blend, Control; Dietary Supplement · Other
Lead sponsor: University of Arizona; Other
Eligibility: 22 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Alzheimer Disease
Interventions: Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo; Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more

Conditions: Psoriasis
Interventions: Cyclosporine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

The Role of Hyperoxia in Acute Ischemic Stroke

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics

The Effect of Perioperative Intravenous Lidocaine Infusion on Opioid Consumption After Lumbar Spine Surgery

Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism

Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

Systemic Lidocaine Infusion for Pain Control in Ventral Hernia

Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism

ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Safety and Efficacy of Empagliflozin in Hemodialysis

Investigational Test of a New Sleep Supplement

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

The Effectiveness of Lower Cyclosporine Doses for Psoriasis